

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

=> s Wyatt, J?/au  
L4 2533 WYATT, J?/AU

=> s 14 and antisense  
L5 69 L4 AND ANTISENSE

=> s 15 and py<=2000  
1 FILES SEARCHED...  
3 FILES SEARCHED...  
L6 22 L5 AND PY<=2000

=> dup 16 remove  
PROCESSING COMPLETED FOR L6  
L7 11 DUP REMOVE L6 (11 DUPLICATES REMOVED)

=> d 17 1-11 abs bib

L7 ANSWER 1 OF 11 CA COPYRIGHT 2002 ACS  
AB The present invention provides compns. and methods for controlling the behavior of a cell, tissue or organism through **antisense** modulation of mRNA processing, using **antisense** compds. which do not support cleavage of the mRNA target. **Antisense** oligonucleotides with 2'-methoxyethoxy (2'-MOE), 2'-dimethylaminooxyethoxy (2'-DMAOE), 2'-dimethylaminoethoxyethoxy, 2'-acetamide, morpholino or peptide nucleic acid modifications were synthesized with phosphodiester or phosphorothioate backbone linkages. The modifications of **antisense** oligonucleotides were either uniform or gapped. Effects of modified **antisense** oligonucleotides on mRNAs were detd. for interleukin 5 (IL-5) receptor .alpha. and Bcl-x. Uniformly 2'-MOE oligonucleotides targeted to certain exons or intron/exon boundaries of the sol./membrane IL-5 receptor .alpha. caused reduced expression of the membrane form and increased expression of the sol. form. Reduced cell surface expression of IL-5 receptor .alpha. protein, induction of apoptosis, and inhibition of cell proliferation in response to IL-5 by the 2'-MOE **antisense** oligonucleotides were also measured. The Bcl-xl (long) isoform of Bcl-x inhibits apoptosis while the Bcl-xs (short) isoform antagonizes Bcl-xl. Uniformly 2'-MOE, phosphorothioate oligonucleotides (e.g. ISIS 22783) targeted to a region upstream of the 5' splice site of bcl-xl were found to increase the ratio of bcl-xs to bcl-xl. After **antisense** treatment with the highly active ISIS 22783, increased apoptosis of cells in response to UV stress, cisplatinum-induced cell death and taxol-induced cell death were quantitated. An ISIS 22783 analog with 2'-DMAOE had a similar effect on the bcl-xs/bcl-xl mRNA ratio.

AN 134:275750 CA

TI Alteration of cellular proliferation or apoptosis by **antisense** modulation of mRNA splicing, polyadenylation, or degradation

IN Bennett, C. Frank; Cooke, Stanley T.; Manoharan, Muthiah; Wyatt, Jacqueline R.; Baker, Brenda F.; Monia, Brett P.; Freier, Susan M.; McKay, Robert; Karras, James G.

PA Isis Pharmaceuticals, Inc., USA

SO U.S., 39 pp., Cont.-in-part of U.S. Ser. No. 167,921.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6210892	B1	20010403	US 1999-277020	19990326
	US 6172216	B1	20010109	US 1998-167921	19981007

US 6214986 B1 20010410 US 1999-323743 19990602  
WO 2000020432 A1 20000413 WO 1999-US22448 19990928 <--  
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,  
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
AU 9962710 A1 20000426 AU 1999-62710 19990928 <--  
EP 1119579 A1 20010801 EP 1999-949943 19990928  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO  
US 2001007025 A1 20010705 US 2000-734846 20001212  
PRAI US 1998-167921 A2 19981007  
US 1999-277020 A2 19990326  
US 1999-323743 A 19990602  
WO 1999-US22448 W 19990928  
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 11 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE  
1  
AB **Antisense** compounds, compositions and methods are provided for  
modulating the expression of E2F transcription factor 3. The compositions  
comprise **antisense** compounds, particularly **antisense**  
oligonucleotides, targeted to nucleic acids encoding E2F transcription  
factor 3. Methods of using these compounds for modulation of E2F  
transcription factor 3 expression and for treatment of diseases associated  
with expression of E2F transcription factor 3 are provided.  
AN 2001:292608 BIOSIS  
DN PREV200100292608  
TI **Antisense** inhibition of E2F transcription factor 3 expression.  
AU Popoff, Ian (1); Wyatt, Jacqueline  
CS (1) Encinitas, CA USA  
ASSIGNEE: Isis Pharmaceuticals, Inc.  
PI US 6165791 December 26, 2000  
SO Official Gazette of the United States Patent and Trademark Office Patents,  
(Dec. 26, 2000) Vol. 1241, No. 4, pp. No Pagination. e-file.  
ISSN: 0098-1133.  
DT Patent  
LA English

L7 ANSWER 3 OF 11 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE  
2  
AB **Antisense** compounds, compositions and methods are provided for  
modulating the expression of methionine aminopeptidase 2. The compositions  
comprise **antisense** compounds, particularly **antisense**  
oligonucleotides, targeted to nucleic acids encoding methionine  
aminopeptidase 2. Methods of using these compounds for modulation of  
methionine aminopeptidase 2 expression and for treatment of diseases  
associated with expression of methionine aminopeptidase 2 are provided.  
AN 2001:244666 BIOSIS  
DN PREV200100244666  
TI **Antisense** inhibition of methionine aminopeptidase 2 expression.  
AU Monia, Brett P.; Wyatt, Jacqueline (1)  
CS (1) Encinitas, CA USA  
ASSIGNEE: Isis Pharmaceuticals Inc.  
PI US 6136604 October 24, 2000  
SO Official Gazette of the United States Patent and Trademark Office Patents,

(Oct. 24, 2000) Vol. 1239, No. 4, pp. No Pagination. e-file.  
ISSN: 0098-1133.

DT Patent  
LA English

L7 ANSWER 4 OF 11 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE  
3

AB Design of **antisense** oligonucleotides targeting any mRNA can be much more efficient when several activity-enhancing motifs are included and activity-decreasing motifs are avoided. This conclusion was made after statistical analysis of data collected from >1000 experiments with phosphorothioate-modified oligonucleotides. Highly significant positive correlation between the presence of motifs CCAC, TCCC, ACTC, GCCA and CTCT in the oligonucleotide and its **antisense** efficiency was demonstrated. In addition, negative correlation was revealed for the motifs GGGG, ACTG, AAA and TAA. It was found that the likelihood of activity of an oligonucleotide against a desired mRNA target is sequence motif content dependent.

AN 2000:403310 BIOSIS

DN PREV200000403310

TI Identification of sequence motifs in oligonucleotides whose presence is correlated with **antisense** activity.

AU Matveeva, O. V. (1); Tsodikov, A. D.; Giddings, M.; Freier, S. M.; Wyatt, J. R.; Spiridonov, A. N.; Shabalina, S. A.; Gesteland, R.

F.; Atkins, J. F.

CS (1) Department of Human Genetics, University of Utah, 15N 2030E Room 7410, Salt Lake City, UT, 84112-5330 USA

SO Nucleic Acids Research, (August 1, 2000) Vol. 28, No. 15, pp. 2862-2865. print.  
ISSN: 0305-1048.

DT Article  
LA English  
SL English

L7 ANSWER 5 OF 11 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE  
4

AB The secondary and tertiary structures of a mRNA are known to effect hybridization efficiency and potency of **antisense** oligonucleotides in vitro. Additional factors including oligonucleotide stability and cellular uptake are also thought to contribute to **antisense** potency in vivo. Each of these factors can be affected by the sequence of the oligonucleotide. Although mRNA structure is presumed to be a critical determinant of **antisense** activity in cells, to date little direct experimental evidence has addressed the significance of structure. In order to determine the importance of mRNA structure on **antisense** activity, oligonucleotide target sites were cloned into a luciferase reporter gene along with adjoining sequence to form known structures. This allowed us to study the effect of target secondary structure on oligonucleotide binding in the cellular environment without changing the sequence of the oligonucleotide. Our results show that structure does play a significant role in determining oligonucleotide efficacy in vivo. We also show that potency of oligonucleotides can be improved by altering chemistry to increase affinity for the mRNA target even in a region that is highly structured.

AN 2000:196376 BIOSIS

DN PREV200000196376

TI Effects of RNA secondary structure on cellular **antisense** activity.

AU Vickers, Timothy A. (1); Wyatt, Jacqueline R.; Freier, Susan M.

CS (1) Department of Molecular and Structural Biology, Isis Pharmaceuticals, 2280 Faraday Avenue, Carlsbad, CA, 92008 USA

SO Nucleic Acids Research, (March 15, 2000) Vol. 28, No. 6, pp.

1340-1347.  
ISSN: 0305-1048.

DT Article  
LA English  
SL English

L7 ANSWER 6 OF 11 CA COPYRIGHT 2002 ACS

AB Iterative, preferably computer-based iterative, processes for generating synthetic compds. with desired phys., chem., and/or bioactive properties are provided. During iterations of the processes, a target nucleic acid sequence is provided or selected, and a library of candidate oligonucleotide sequences is generated in silico according to defined criteria. A "virtual" oligonucleotide chem. is chosen and a library of virtual oligonucleotides having the selected sequences is generated. These virtual compds. are reviewed and compds. predicted to have particular properties are selected. The selected compds. are robotically synthesized and are preferably robotically assayed for a desired phys., chem., or biol. activity. Active compds. are thus generated and, at the same time, preferred sequences and regions of the target nucleic acid that are amenable to oligonucleotide or sequence-based modulation are identified. The method was employed to identify phosphorothioate oligonucleotides targeted to CD40, RhoC, API-2, ELK-1, G.alpha.11, and AKT-1.

AN 131:307654 CA

TI Identification of genetic targets for oligonucleotides and generation of oligonucleotides for gene modulation

IN Cowser, Lex M.; Baker, Brenda F.; Mcneil, John; Freier, Susan M.; Sasmor, Henri M.; Brooks, Douglas G.; Ohasi, Cara; **Wyatt, Jacqueline R.**; Borchers, Alexander H.; Vickers, Timothy A.

PA Isis Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 264 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9953101	A1	19991021	WO 1999-US8268	19990413 <--
	W:				AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
	RW:				GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
	US 2002028923	A1	20020307	US 1998-67638	19980428
	CA 2325013	AA	19991021	CA 1999-2325013	19990413 <--
	AU 9939650	A1	19991101	AU 1999-39650	19990413 <--
	EP 1071826	A1	20010131	EP 1999-922713	19990413
	R:				AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
	JP 2002511276	T2	20020416	JP 2000-543647	19990413
PRAI	US 1998-81483P	P	19980413		
	US 1998-67638	A2	19980428		
	WO 1999-US8268	W	19990413		

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 11 SCISEARCH COPYRIGHT 2002 ISI (R)

AB A computer program, OligoWalk, is reported that predicts the

equilibrium affinity of complementary DNA or RNA oligonucleotides to an RNA target. This program considers the predicted stability of the oligonucleotide-target helix and the competition with predicted secondary structure of both the target and the oligonucleotide. Both unimolecular and bimolecular oligonucleotide self structure are considered with a user-defined concentration. The application of OligoWalk is illustrated with three comparisons to experimental results drawn from the literature.

- AN 1999:891635 SCISEARCH  
GA The Genuine Article (R) Number: 255MD  
TI Predicting oligonucleotide affinity to nucleic acid targets  
AU Mathews D H; Burkard M E; Freier S M; Wyatt J R; Turner D H  
(Reprint)  
CS UNIV ROCHESTER, DEPT CHEM, ROCHESTER, NY 14627 (Reprint); UNIV ROCHESTER, DEPT CHEM, ROCHESTER, NY 14627; ISIS PHARMACEUT, DIV MOL & STRUCT BIOL, CARLSBAD, CA 92008  
CYA USA  
SO RNA-A PUBLICATION OF THE RNA SOCIETY, (NOV 1999) Vol. 5, No. 11, pp. 1458-1469.  
Publisher: CAMBRIDGE UNIV PRESS, 40 WEST 20TH STREET, NEW YORK, NY 10011-4211.  
ISSN: 1355-8382.  
DT Article; Journal  
FS LIFE  
LA English  
REC Reference Count: 52  
\*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*
- L7 ANSWER 8 OF 11 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 5  
AB Resistance to apoptosis, which plays an important role in tumors that are refractory to chemotherapy, is regulated by the ratio of antiapoptotic to proapoptotic proteins. By manipulating levels of these proteins, cells can become sensitized to undergo apoptosis in response to chemotherapeutic agents. Alternative splicing of the bcl-x gene gives rise to two proteins with antagonistic functions: Bcl-xL, a well-characterized antiapoptotic protein, and Bcl-xS, a proapoptotic protein. We show here that altering the ratio of Bcl-xL to Bcl-xS in the cell using an **antisense** oligonucleotide permitted cells to be sensitized to undergo apoptosis in response to ultraviolet B radiation and chemotherapeutic drug treatment. These results demonstrate the ability of a chemically modified oligonucleotide to alter splice site selection in an endogenous gene and illustrate a powerful tool to regulate cell survival.  
AN 2000:42175 BIOSIS  
DN PREV200000042175  
TI Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by **antisense** oligonucleotides.  
AU Taylor, Jennifer K.; Zhang, Qing Qing; Wyatt, Jacqueline R.; Dean, Nicholas M. (1)  
CS (1) Department of Pharmacology, Isis Pharmaceuticals, Carlsbad, CA USA  
SO Nature Biotechnology, (Nov., 1999) Vol. 17, No. 11, pp. 1097-1100.  
ISSN: 1087-0156.  
DT Article  
LA English  
SL English
- L7 ANSWER 9 OF 11 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1999:184663 BIOSIS  
DN PREV199900184663  
TI Upregulation of Bcl-xs through modulation of Bcl-x splicing by chemically modified **antisense** oligonucleotides.  
AU Taylor, J. K.; Zhang, Q. Q.; Burkin, T.; Cooper, S.; Wyatt, J.;

Freier, S.; Dean, N. M.  
 CS Isis Pharm., Carlsbad, CA 92075 USA  
 SO Proceedings of the American Association for Cancer Research Annual  
 Meeting, (March, 1999) Vol. 40, pp. 217-218.  
 Meeting Info.: 90th Annual Meeting of the American Association for Cancer  
 Research Philadelphia, Pennsylvania, USA April 10-14, 1999 American  
 Association for Cancer Research  
 . ISSN: 0197-016X.  
 DT Conference  
 LA English

L7 ANSWER 10 OF 11 CA COPYRIGHT 2002 ACS  
 AB Comps. and methods are provided for the treatment and diagnosis of  
 herpesvirus infections. In accordance with preferred embodiments,  
 oligonucleotides are provided which are specifically hybridizable with RNA  
 or DNA deriving from a herpesvirus gene corresponding to one of the open  
 reading frames UL5, UL8, UL9, UL20, UL27, UL29, UL30, UL42, UL52 and IE175  
 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide  
 units sufficient in identity and no. to effect said specific  
 hybridization. In other preferred embodiments, the oligonucleotides are  
 specifically hybridizable with a translation initiation site, a coding  
 region or a 5'-untranslated region. Methods of treating animals suspected  
 of being infected with herpesvirus comprising contacting the animal with  
 an oligonucleotide of the invention are disclosed. Methods for treatment  
 of infections caused by herpes simplex virus type 1, herpes simplex virus  
 type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or  
 varicella zoster virus are disclosed.

AN 125:49274 CA  
 TI Oligonucleotide therapies for modulating the effects of herpes viruses  
 IN Draper, Kenneth G.; Crooke, Stanley T.; Mirabelli, Christopher K.; Ecker,  
 David J.; Hanecak, Ronnie C.; Anderson, Kevin P.; Brown-Driver, Vickie L.;  
 Wyatt, Jacqueline R.  
 PA Isis Pharmaceuticals, Inc., USA  
 SO U.S., 28 pp. Cont.-in-part of U.S. 5, 248, 670.  
 CODEN: USXXAM

DT Patent  
 LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5514577	A	19960507	US 1993-31147	19930312 <--
	US 5248670	A	19930928	US 1990-485297	19900226 <--
	US 6310044	B1	20011030	US 1992-852132	19920428
	EP 1016715	A1	20000705	EP 1999-203835	19930929 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
WO	9419945	A1	19940915	WO 1994-US2471	19940307 <--
	W: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV,				
	MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,				
	BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU	9463619	A1	19940926	AU 1994-63619	19940307 <--
EP	692930	A1	19960124	EP 1994-910879	19940307 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP	08503959	T2	19960430	JP 1994-520254	19940307 <--
US	5658891	A	19970819	US 1994-329212	19941026 <--
PRAI	US 1990-485297	A2	19900226		
	US 1992-852132	A2	19920428		
	US 1992-954185	B2	19920929		
	WO 1991-US1327	W	19910225		
	US 1993-31147	A	19930312		
	US 1993-122328	B1	19930916		
	EP 1993-922788	A3	19930929		

L7 ANSWER 11 OF 11 SCISEARCH COPYRIGHT 2002 ISI (R)  
 AB Phosphorothioate oligonucleotides were identified which directly inhibited human type II phospholipase A(2) (PLA(2)) enzyme activity in a sequence specific manner. The minimum pharmacophore common to all oligonucleotides which inhibited FLAP enzyme activity consisted of two sets of three or more consecutive guanosine residues in a row. These oligonucleotides appear to form G quartets resulting in the formation of oligonucleotide aggregates. Additionally, a phosphorothioate backbone was required to be effective inhibitors of type II PLA(2). The activity of one oligodeoxynucleotide, IP 3196 (6'-GGGTGGGTATAGAAGGGCTCC-3') has been characterized in more detail. IP 3196 inhibited PLA(2) enzyme activity when the substrate was presented in the form of a phospholipid bilayer but not when presented in the form of a mixed micelle with anionic detergents. Human type II PLA, was 50-fold more sensitive to inhibition by IP 3196 than venom and pancreatic type I enzymes. These data demonstrate that phosphorothioate oligonucleotides can specifically inhibit human type II PLA(2) enzyme activity in a sequence specific manner.

AN 94:537131 SCISEARCH  
 GA The Genuine Article (R) Number: PD657  
 TI SEQUENCE-SPECIFIC INHIBITION OF HUMAN TYPE-II PHOSPHOLIPASE A(2) ENZYME-ACTIVITY BY PHOSPHOROTHIOATE OLIGONUCLEOTIDES  
 AU BENNETT C F (Reprint); CHIANG M Y; WILSONLINGARDO L; WYATT J R  
 CS ISIS PHARMACEUT, DEPT MOLEC PHARMACOL, 2292 FARADAY AVE, CARLSBAD, CA, 92008 (Reprint); ISIS PHARMACEUT, DEPT BIOL MOLEC & STRUCT, CARLSBAD, CA, 92008  
 CYA USA  
 SO NUCLEIC ACIDS RESEARCH, (11 AUG 1994) Vol. 22, No. 15, pp. 3202-3209.  
 ISSN: 0305-1048.  
 DT Article; Journal  
 FS LIFE  
 LA ENGLISH  
 REC Reference Count: 63  
 \*ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS\*

=>